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Abstract: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal 
tumors of the gastrointestinal tract. They are characterized by gain of function mutations in 
KIT or PDGFRA tyrosine kinase receptors, with their consequent constitutive activation. 
The gold standard therapy is imatinib that offers a good and stable response for 
approximately 18–36 months. However, resistance is very common and it is vital to 
identify new biomarkers. Up until now, there have been two main approaches with focus to 
characterize novel targets. On the one hand, the focus is on the tumor genome, as the final 
clinical outcome depends mainly from the cancer specific mutations/alterations patterns. 
However, the germline DNA is important as well, and it is inconceivable to think the 
patients response to the drug is not related to it. Therefore the aim of this review is to 
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outline the state of the art of the personalized medicine in GIST taking into account both 
the tumor DNA (somatic) and the patient DNA (germline). 
Keywords: GIST; KIT/PDGFRA mutant GIST; WT-GIST; personalized therapy; biomarkers; 
drug resistance; polymorphisms 
 
1. Introduction 
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the 
gastrointestinal  tract and are worldwide considered a paradigm of molecular biology in solid  
tumors [1]. Everything has begun with the introduction of tyrosine-kinase inhibitors (TKI) that 
positively affected the long-term prognosis of GIST patients, tremendously modifying the natural 
history of this rare disease [2–4]. Imatinib was the first TKI introduced in GIST management in 2000, 
and still remains the only approved first line treatment, while sunitinib and regorafenib represent the 
second and third line treatment, respectively [2,3]. 
The GIST paradigm has been proven to be more complex than expected, due to the evidence of  
a molecular heterogeneity within all GIST tumors, and the identification of different subgroups 
frequently characterized by a peculiar genotype-phenotype [5]. With the discovery of the common and 
mutually exclusive KIT or platelet-derived growth factor receptor alpha (PDGFRA) gain-of-function 
mutations, which occur in about 70%–80% and 7% of cases respectively, deeper insights on GIST 
biology have been progressively gained. Specifically, with the application of high throughput 
technologies into basic and translational research, we experienced the identification of a wide spectrum 
of other genomic alterations [6–10]. The biological role of most of these additional events in GIST 
pathogenesis and development remains undefined. However, it is known that acquisition of secondary 
resistance to TKIs’ frequently shows substantial heterogeneity within and between metastases from 
individual patients [11]. 
Tumor handling is, and has been for a long time, one of the most difficult issues. In the era of 
personalized medicine, clinicians are faced with many intriguing doubts regarding the choice of the 
adequate drug administered at the correct dosage, for a certain patient. Unfortunately, regarding GIST 
patients, clinicians do not have a real choice since only TKIs are approved for GIST treatment, even 
for patients without TK-gain of function mutations. In this context, the rapid progress of high-throughput 
genome sequencing, applied to molecular diagnosis, has the potential to drive the development and 
approval of new therapeutic options for GIST patients resistant to TKIs or with mutations in genes 
other than TK [12]. What is known to be sure is that two main players are involved in the final clinical 
outcome: the somatic DNA and the germline DNA [12]. The somatic genome represents the specific 
tumor DNA and includes all the mutations and alterations strictly associated with the cancer. The germline 
DNA represents the patient’s genome. These two genomes together are relevant in cancer treatment, 
dictating response and toxicity. In particular the somatic DNA influences the tumor behavior and 
aggressiveness, and mainly it determines the responsiveness to the treatment; germline DNA primarily 
influences drug exposure (how the body handles) and toxicity (how the body reacts) [12]. 
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In this view, scientists and clinicians are obligated to take into account that both DNAs supply 
specific biomarkers which together affect the patient’s drug response. Therefore, from the era of 
targeted therapies we are moving towards the era of personalized therapies, which should take into 
account all genomic variables, both the tumors and the patients, making GIST a more actual model in 
the molecular biology of solid tumors. In light of these considerations, the integrated study of the 
somatic genome and the germline DNA certainly represents a major step towards the translation of 
personalized therapy into clinical practice. 
The aim of this review is to outline the state of the art of the personalized medicine in GIST 
considering two sides of the same coin: on the one hand the tumor DNA, with its mutations pattern that 
strictly typify the cancer, and on the other hand the patient DNA, that could contribute to the clinical 
outcome as well. 
2. Pharmacogenetic Approaches in GIST: State of the Art 
As mentioned above, approximately 80% of GIST harbors KIT/PDGFRA mutations, however, 
unfortunately, there are not inherited genetic factors. Epidemiological studies have raised the 
possibility that risk factors, e.g., dioxin and radiation exposure, may be linked to sarcomas [13]. In 
regard to these considerations, O’Brien and colleagues analyzed 208 variants in 39 candidate genes 
related to DNA repair and dioxin metabolism and imatinib response in 279 GIST enrolled in a clinical 
trial for neoadjuvant imatinib. In particular, they found that polymorphisms in CYP1B1 (rs2855658 
and rs1056836) were strongly associated with the presence of KIT exon 11 codon 557-8 deletions  
(p = 0.002 and p = 0.004, respectively). Moreover, they found other potential risk variants such as 
RAD23B, ERCC2 and GSTM1, highlighting the hypothesis of an environmental related origin of 
GIST [13]. Up until now, no additional studies have been performed to confirm these findings, and this 
represents the only study, conducted through the high throughput screening platform (Illumina), 
related to germline variants in GIST. 
After imatinib introduction in therapy, GIST patients’ prognosis and survival improved  
significantly [6,14]. However, despite the excellent results, it is common that patients initially 
responding well to imatinib, develop progression and acquired resistance through different  
mechanisms [6,14]. In this view, the major efforts of researchers have focused on identifying the  
driver mechanisms of acquired resistance as well as novel potential biomarkers for GIST treatment. 
Though it is likely that in drug response the significance of the tumor DNA weighs more than the 
germinal one, the genetic code of the patient still remains relevant. Indeed, it is well known that any 
drug, starting from its intake, undergoes a specific pharmacokinetics itinerary, and a growing body of 
literature ascribes to this itinerary a role in drug efficacy and side effects [15]. 
Figure 1 shows the main actors taking part in the resulting imatinib bioavailability; imatinib is  
almost completely absorbed (~97%) [16], and it is widely metabolized in the liver by the cytochrome 
P450 isoforms 3A4 and 3A5, while proteins as OCT1, OCTN, OATP, ABCB1 and ABCG2 are 
transporters affecting its efflux and uptake. As a result, it seems obvious that polymorphisms in genes 
coding these metabolizing and transporter enzymes could make the differences in the resulting 
proteins. In a previous pharmacogenetic study evaluating chronic myeloid leukemia (CML) patients 
undergoing imatinib therapy, an association between imatinib transporter genotype and imatinib 
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response has been found [17]. On the basis of these findings, in 2013, Angelini and colleagues conducted 
the first pharmacogenetic study on GIST patients undergoing imatinib therapy. Through a multiple 
candidate gene approach, they analyzed a panel of 31 single nucleotide variants in nine transporters 
genes and two metabolizing genes in 54 GIST patients treated with imatinib. They found three 
polymorphisms, one in SLC22A4 (rs105152) and two in SLC22A5 (rs263136, and rs231372)—coding 
for OCTN1 and OCTN2 transporters respectively—associated with a significant improvement in the 
time to progression (TTP) [18]. Interestingly, this study confirmed a previous finding in CML patients, 
highlighting the involvement of the OCTN1 polymorphisms (rs105152) in imatinib response [17]. 
 
Figure 1. The main players in imatinib pharmacokinetics. 
More recently, Koo et al. reported a polymorphism in ABCG2 (rs2231142) associated with  
five-year progression-free survival (PFS) in 209 GIST treated with imatinib 400 mg/daily; in 
particular, carriers of the AA genotype had a longer PFS compared with GG or AG carriers [19]. This 
represents an intriguing finding as the same polymorphism has been analyzed by Angelini et al. 
showing no significant correlation. The discrepancy might be due to the small GIST population 
analyzed by Angelini et al. (54 vs 209 GIST patients), with a consequent low statistical power, which 
might not have revealed the significance [17,19]. To the best of our knowledge, there are no additional 
studies in GIST reporting on polymorphisms in imatinib transporters and metabolizing genes. 
In the last years, growing evidence of a strict link between aberrant methylation profile and cancer, 
as well as neurodegenerative diseases, have been reported [20,21]. In particular, a recent finding 
suggests the DNA methylation pattern may be associated with aggressive clinical behavior and 
unfavorable prognosis in GIST [22]. Based on these findings, and considering that the genes coding for 
enzymes involved in the folate pathway could impact the methylation processes, Angelini et al. 
evaluated 13 common polymorphisms in eight of the main folate-related genes, in 60 GIST patients 
and 153 healthy controls. The data highlighted a decreased risk of GIST associated with a six bp 
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deletion in the thymidylate synthase (TS) gene (formerly rs34489327, delTInsTTAAAG), and a 
reduced TTP associated with the wild-type allele in the reduced folate carrier (RFC) [23]. All these 
results, taken together, suggest the importance of germline genetic variations in genes involved in key 
pathways, including drug uptake and efflux, and in the accurate regulation of the balance in 
methylation rate. 
The importance of the patient’s DNA is also supported by new evidence reinforcing the role of 
plasma level regulation in assessing the response rate. In 2010, for the first time, Yoo et al. examined 
imatinib plasma trough levels (Cmin) in GIST patients treated with imatinib 400 mg/daily [24]. Among 
all patients’ and tumor characteristics, the most interesting finding is that major gastrectomy was 
associated with lower imatinib Cmin when compared to a more conservative gastric resection. This 
observation suggests that monitoring imatinib Cmin might be particularly important for optimal 
treatment in patients who have undergone major gastrectomy, as imatinib 400 mg/daily might be 
insufficient to maintain an optimal blood level, and can be responsible of a poor PFS. However, from 
this study it is difficult to draw a definitive conclusion on the clinical utility of plasma trough levels 
monitoring, considering that data on imatinib response were not taken into account [24]. Two years 
later, Eechoute and colleagues carried out the first prospective pharmacokinetic study in 50 GIST 
patients, revealing a substantial decrease of approximately 30% in imatinib exposure after long-term 
treatment, in part due to reduced absorption. According to these results, the authors, in order to get 
clinical benefits, suggest a different approach that, besides tumor biology, considers also patient 
characteristics, in particular time point-specific imatinib trough level determination [25]. The same 
approach has been recommended by Yoon et al. that described two case reports with advanced GIST 
for which imatinib-related toxicities were successfully managed through dose modifications via 
imatinib plasma level testing [26]. Taken together, these findings indicated that a fine dose adjustment, 
guided by imatinib plasma level measurement, could prevent over-exposure and the resulting toxicity 
without affecting its efficacy [25,26]. An important consideration regarding the clinical utility of 
plasma trough levels monitoring is that optimal threshold value of imatinib Cmin has yet to be 
determined in GIST patients. Furthermore, even if treatment failure or toxicities could occur with an 
inappropriate dosing, and imatinib trough levels monitoring could in turn prevent inappropriate dosing, 
this has not been sufficiently investigated in clinical practice. However, an interesting scenario that  
has emerged from these studies is that inter-individual differences could impact the resulting drug 
clearance or the amount of protein bound drug. Unfortunately, to the best of our knowledge, there are 
no studies in GIST patients evaluating the influence of polymorphisms in imatinib clearance. Interestingly, 
stimulating information comes from CML patients undergoing imatinib treatment. In particular,  
Di Paolo et al. reported a correlation between the hOCT1 polymorphisms (c.480C>G, rs683369) and 
drug clearance in 60 CML patients treated with imatinib [27]. In this study, patients carrying at least 
one polymorphic G-allele had a significantly lower drug clearance than CC carriers. This intriguing 
finding should stimulate further research in GIST patients and, if validated, it could be useful in 
choosing the most effective dose with the as low toxicity as possible. 
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Table 1. Summary of the pharmaocogenetics studies. 
Authors Year 
#n of the Evaluated 
SNPs and Pathway  
Gene/Reference Sequence (rs) * #n of Cases Aim Significant SNPs 
O’Brien et al 
[13]. 
2013 
208 SNVs in  
39 candidate genes 




CYP1A2, CYP1B1, HIF1A, NQO1, G6PC/G6PT, 
ADH1A, ADH1B, ADH1C, ALDH18A1, ALDH1A1, 
ALDH1A2, ALDH1A3, ALDH1B1, ALDH1L1, 
ALDH1L2, ALDH2, CYP2B6, CYP2C8, CYP2C9, 
CYP2D6, CYP2E1, CYP3A4, GSTM1, GSTT1, GSTP1, 
HNF4A, NAT2, NFE2L2, NOS2A, PTGS2/COX2, 
SULT1A1, TP53, MDM2. 
279 GIST from 




To test the association 
between germline SNVs 
and somatic mutations 
and to evaluate the 
hypothesis of 
environmental related 
origin for GIST 
CYP1B1 rs2855658 and rs1056836 were 
associated with KIT exon 11 codon 557-8 
del; ERCC2 rs50871 was associated with 
WT GIST; ERCC2 rs50871 was 
associated with KIT exon 11 insertion  
(no codon 557-8); GSTM1 deletion was 
associated with KIT exon 11 codon 557-8 
del; RAD23B rs1805329 and rs7041137 
were associated with other KIT mutations 
(none in exon 11) 
Angelini et al 
[18]. 
2013 
27 SNVs in 9 
transporters genes;  
4 SNVs in  
4 metabolizing genes 
SLC22A1 (rs12208357, rs683369, rs4646277, 
rs4646278, rs2282143, rs72552763); SLC22A4 
(rs1050152); SLC22A5 (rs2631367, rs2631370, 
rs2631372); SLCO1A2 (rs11568563); SLCO1B3 
(rs4149157, rs4149158, rs4149117, rs7311358); 
ABCA3 (rs323040, rs4146825); ABCB1 (rs10245483, 
rs3213619, rs1128501, rs1128503, rs60023214, 
rs2032582); ABCC4 (rs3765534, rs9561765); ABCG2 
(rs2231137, rs2231142); CYP3A4 (rs2740574, 




imatinib 400 mg 
To evaluate the 
correlation among SNPs 
and clinical outcome 
TTP improved by C allele in SLC22A4 
(rs1050152; p = 0.013), and by G alleles 
in SLC22A5 (s2631367; p = 0.042) and 
(rs2631372; p = 0.045) 
Koo et al [19]. 2015 
5 SNVs in  
2 transporters genes; 
1 SNVs in  
1 metabolizing genes 
ABCB1 (rs1128503, rs1045642, rs2032582); ABCG2 




imatinib 400 mg 
To evaluate the 
correlation among SNPs 
and clinical outcome 
The 5-year PFS rate in patients with the 
AA variant of ABCG2 rs2032582 was 
superior compared with patients with 
CC/CA genotypes (p = 0.047) 
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Table 1. Cont. 
Authors Year 
#n of the Evaluated 
SNPs and Pathway 
Gene/Reference Sequence (rs) * #n of Cases Aim Significant SNPs 
Angelini et al 
[23]. 
2015 
13 SNVs in 8 folate 
pathway genes 
RFC (rs1051266); FOLR (rs2071010); DHFR 
(rs70991108); TS (rs45445694, rs34489327); SHMT 
(rs1979277); MTHFR (rs1801131, rs1801133); 
MTR (rs1805087); MTRR (rs10380). 
60 GIST patients 
receiving imatinib  
400 mg and  
153 controls 
To evaluate the 
correlation among SNPs 
and clinical outcome 
In 54 patients, presence of WT allele in 
RFC rs1051266, (AA/AG) was associated 
with reduced TTP (p = 0.028) 
Rutkowski et al 
[28]. 
2012 
6 SNVs in 2 VEGF 
pathway genes 
VEGFA (rs699947, rs3025039,rs2010963, 
rs833061); VEGFR2 (1531289, rs1870377). 
39 GIST patients 
receiving sunitinib 
2nd line treatment 
50 mg 
To evaluate the 
correlation among  
SNPs and adverse 
reactions or toxicity 
Presence C-allele in VEGFA rs833061 
and the T-allele in rs3025039 were 
associated with higher risk of 
hypothyroidism (p = 0.041 and p = 0.015, 
respectively) 
* The polymorphisms analyzed by multiple studies are highlighted in red. 
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To date, most of the pharmacogenetics literature is centered on imatinib while the potential 
associations with sunitinib or regorafenib have not been taken into account. The only exception is 
represented by the work of Rutkowski and colleagues who described the outcome and potential 
predictive factors in GIST patients treated with sunitinib after imatinib failure [28]. In this study, six 
polymorphisms in genes belonging to the vascular endothelial growth factor (VEGF) pathway were 
evaluated. Sunitinib is a multitargeted agent, an inhibitor of tyrosine kinases, including KIT, 
PDGFRA/B and the VEGFR receptors −1 and −2. Therefore, as sunitinib acts through the VEGF 
signaling cascade, authors investigated the influence of VEGFA and VEGFR2 polymorphisms on 
sunitinib toxicity, highlighting a likely link between sunitinib-induced hypothyroidism [28]. 
Regrettably, given the small population size of 39 cases, the authors did not evaluate any possible 
association with the clinical outcome and at the moment no data are available. Table 1 summarizes the 
studies and shows the polymorphisms identified as involved in the pharmacogenetics of GIST. To the 
best of our knowledge, no other pharmacogenetic studies have been conducted on sunitinib or 
regorafenib. However, considering the similar pharmacokinetics of the two drugs with the cytochrome 
P450 isoforms 3A4 and 3A5 as main players in their metabolisms, and proteins ABCB1 and ABCG2 
as transporters, it is plausible that polymorphisms in these genes may also affect their clinical utility. 
A fascinating part of pharmacogenetics is left for the emerging role of microRNAs as potentially 
responsible for clinical outcome variability. MicroRNAs are a class of 18–24 nucleotides long noncoding 
RNAs, playing an important role in significant biological processes, such as differentiation, proliferation 
and apoptosis [29]. MicroRNAs alteration represents epigenetic modifications that are emerging as 
having a relevant role in GIST biology, including disease development and progression, clinical 
outcome and drug resistance [30]. Unfortunately, as highlighted by Nannini et al., despite the growing 
evidence of the importance of microRNAs in GIST, there is a small consensus among the microRNA 
signature between the different studies [31]. However, the majority of them agreed about the involvement 
in GIST pathogenesis of miR-221 and miR-222, which have been reported by four independent groups 
as implicated in KIT expression regulation [32–35]. In particular, it has been demonstrated that their 
overexpression negatively regulates the TK receptor expression rate and consequently miR-221 and 
222 could be realistically developed as therapeutic-targets for GIST management. 
3. Analysis in Somatic DNA 
The detection of somatic mutations from cancer genome sequences is the key to understanding the 
genetic basis of disease progression, patient survival, therapy response and toxicity. The tumor DNA is 
the main source of information, which has led over the years to a more detailed characterization of the 
biological profile of GIST. According to the somatic genome, GIST are divided into KIT/PDGFRA 
mutant GIST and wild-type (WT) GIST, characterized by deep differences in imatinib response.  
GIST KIT exon 11 mutants manifest response rate in 80% of cases, KIT exon 9 in 40%, and GIST WT 
in 14%. PDGFRA mutants show a mild sensitivity to imatinib (66%), with the exception of exon 18 
point mutation (D842V), which is totally resistant [10–12]. 
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3.1. KIT/PDGFRA Mutant GIST 
From the beginning, the kinase mutational status has represented the peculiar molecular hallmark of 
GIST, and has been recognized as the main pathogenic event as well as the best known predictive 
biomarker of tumor response to TKI [36–39]. Besides the importance of GIST mutational status in 
predicting imatinib sensitivity, as described above, the acquisition of secondary mutations in either 
KIT or PDGFRA represents the most frequent mechanism of imatinib resistance in GIST. The 
acquisition of additional KIT and PDGFRA mutations, occurs with a median of 24 months and shows 
a typical heterogeneous distribution within each lesion [40]. However, other molecular events beyond 
KIT and PDGFRA mutations may play a relevant role in GIST pathogenesis and progression, even if 
at the moment they remain still unidentified. For example, it has been shown that micro-GIST, defined 
as GIST smaller than 1 cm, can display KIT/PDGFRA mutations and, at the same time, carry rare  
and novel mutations, suggesting that, actually, other pathogenic molecular events, besides kinase 
mutations, could occur [41]. Furthermore, secondary resistance can also occur without the onset of 
secondary KIT/PDGFRA mutations, suggesting that other driven molecular events can play a relevant 
role in GIST biology. So, in recent years, with the use of increasingly innovative high throughput 
technologies, many efforts have been made in order to better characterize the molecular background of 
each GIST subtype. This, in the long run will lead to the identification of novel targets, thus expanding 
the armamentarium of GIST therapies available to clinicians. Most of the studies showed that GIST 
display cytogenetic aberrations, with the highest occurrence of 1p, 13q, 14q, and 15q loss, and 22q loss 
of heterozygosity. Interestingly, this unstable karyotype typifies mutant GIST, whereas WT GIST do 
not show genomic imbalances [8,42–44]. Integrating the high-resolution genomic copy number 
analysis with gene expression profiling, some known oncogenes, including KRAS in chromosome 12p 
amplification, and some tumor suppressors genes, such as KIF1B, PPM1A, and NF2 on chromosome 
1p, 14q and 22p deletions, respectively, have been found. Moreover, other tumor suppressor genes, 
including DAAM1, RTN1 and DACT1 have been restricted to the 14q23.1 region, which represents 
the genomic segment most frequently altered in mutant GIST [8]. In a further study, it has been shown 
that the ETS family transcription factor, ETV1, is universally highly expressed in GIST, both at protein 
and mRNA levels, and at higher levels than any other tumor type, including melanoma and prostate 
cancer [44]. Additionally ETV1 is required for tumor growth and survival in both imatinib-sensitive 
(GIST882) and imatinib-resistant (GIST48) cell lines. Furthermore, ETV1 is highly expressed in the 
subtypes of interstitial cells of Cajal (ICC)—the presumed GIST cell of origin—sensitive to oncogenic 
KIT mediated transformation, and required for their development into GIST [44]. ETV1 is a master 
regulator of the ICC lineage, and a recent study in a mouse model of KIT activation and ETV1 ablation 
has demonstrated that ETV1 is required for GIST initiation and proliferation in vivo [45]. Furthermore, 
a positive feedback circuit involving MAPK signaling, that stabilizes ETV1 protein, which in turn 
positively regulates KIT expression has been found [45]. Taken together, these results suggest that 
ETV1 may be considered a new key therapeutic target in GIST, with the potential to revolutionize the 
first-line treatment of GIST patients [45]. 
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3.2. Wild-Type GIST 
While the efforts for mutant GIST have been addressed to the discovery of other oncogenic events 
beyond KIT and PDGFRA, the efforts for KIT/PDGFRA WT GIST have been directed to the 
identification of the molecular signature of this small subset of GIST. For a long time, WT GIST have 
been viewed as a unique and less frequent subgroup of GIST, characterized by the lack of known KIT 
and PDGFRA mutations. Advances in science, culminating with whole genome analysis have shown 
that KIT/PDGFRA WT GIST should be considered more appropriately as a heterogeneous family of 
distinct disease entities, with different biological and clinical features [46]. As previously highlighted, 
WT GIST are characterized by an imatinib response rate of 14%, requiring the identification of novel 
targets and the development of new therapeutic strategies. About 15% of KIT/PDGFRA WT GIST 
harbors activating mutation in BRAF or, more rarely, RAS gene [47]. Effective treatments for  
BRAF-mutant GIST might be the use of a BRAF inhibitor such as dabrafenib, which is active in 
several BRAF-mutant cancers [48]. To the best of our knowledge, the efficacy of BRAF inhibitors in  
BRAF-mutant GIST has not been reported, however, there is a case of prolonged antitumor activity  
in a BRAF-mutant GIST, which suggests the need for additional studies and perhaps a global clinical 
trial [49]. 
In addition, KIT/PDGFRA WT GIST may be related to syndromic neurofibromatosis type I (NF1) 
disease, associated with NF1 protein loss of function due to genomic inactivation of the NF1 gene [50]. 
Moreover, about 20%–40% of KIT/PDGFRA WT GIST shows a loss of function of the succinate 
dehydrogenase (SDH) complex, identified with the loss of the subunit B (SDHB) protein expression 
and referred as SDH-deficient GIST or type 2 GIST. All the SDHB immunohistochemical-negative GIST 
are also characterized by an over expression of the insulin growth factor 1 receptor (IGF1R) [51,52]. 
With regard to SDH-deficient GIST, they display distinctive clinic-pathological features, including 
predominance in young (<40 years) women, gastric localization, multifocality, mixed epitheliod and 
spindle cell morphology, diffuse KIT and DOG1 positivity, frequent lymphonode metastases, and an 
indolent course, although it is often metastatic when diagnosed [53]. In most cases, SDH-deficient 
GIST harbor germline and/or somatic loss-of-function mutations in any of the four SDH subunits (A, 
B, C, or D; SDHx), with the highest occurrence of SDHA mutations [54,55]. More recently, it has been  
shown that loss of SDHB protein expression, not driven by SDHx mutations, might be due to a 
hypermethylation in the SDHC promoter region [9,56]. 
Most recently, a small subgroup of KIT/PDGFRA WT GIST, referred as quadruple WT GIST, that 
lack mutations in any of the known KIT exons (8, 9, 11, 13, 14, 17) or PDGFRA exons (12, 14, 18) or 
RAS pathways, including BRAF (exons 11, 15) and RAS (exons 2, 3), or NF1, and yet retain an intact 
SDH complex (SDHB IHC positive, and no mutations in SDHx) has been identified [57,58]. A whole 
genome analysis, using massively parallel sequencing and gene expression analysis, has shown that 
quadruple WT GIST have an expression signature extremely different from both KIT/PDGFRA 
mutated and SDHA mutated GIST, characterized by the overexpression of molecular markers 
(CALCRL and COL22A1) and of specific oncogenes, including tyrosine and cyclin-dependent kinases 
(NTRK2 and CDK6), and one member of the ETS-transcription factor family (ERG) [58]. 
All this evidence together reveals that GIST should be considered as a distinctive set of biological 
entities, and it would be wise to take into consideration all these genomic variables when selecting the 
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medical treatment. Unfortunately, the high cost associated with genomic analysis, as well as the need 
of specialized laboratories and tools, and the need of fresh tumor tissue for analysis, restrict the 
realization and its application in clinical practice. For these reasons, in recent years, the DNA extracted 
from formalin-fixed, paraffin-embedded specimens and, more recently, the circulating tumor DNA 
(ctDNA) obtained from a patient’s bloodstream, known as liquid biopsy, have become the most 
potential and promising source of tumor DNA [59,60]. In particular, the possibility to extend sophisticated 
analysis with high-throughput technologies on all archived specimens, may allow genomic studies on  
a wider number of samples, and thereby improve the knowledge of the biological background of all 
subsets of GIST. Furthermore, in view of a personalized therapy, serial evaluations of ctDNA may 
offer a dynamic picture of the molecular changes during the course of the disease, in order to identify 
the early development of heterogeneous resistant clones, allowing optimizing the time to switch the 
treatment, as well as the choice of the right treatment. All this should lead to the identification of the 
optimal therapeutic strategy  for each individual patient. 
4. Conclusions 
The prognosis for GIST patients has changed enormously over the last decades. In particular, 
imatinib has radically changed life expectancy of patients with GIST, a previously largely untreatable 
group of patients. However, imatinib has not proven to be the definitive answer for their management. 
For those with disease refractory to imatinib, as well as the great majority who develop resistance to 
imatinib, other TKI, sunitinib and regorafenib, are available. It is clear that, at the moment, TKIs are 
the only available treatment in GIST, however, with the development of high throughput technologies, 
as next generation sequencing, and the use of ctDNA, new targets will be available and new targeted 
therapies will be developed. The increasing number of targeted agents, which hold promise for 
improving outcomes in patients with GIST, raises interesting questions about the optimal utilization of 
these agents and the development of pharmacogenetics tests. In the most ideal situation pharmacogenetics 
will allow oncologists to individualize therapy based on somatic and germline genetic test results. 
Overall, this can help to improve efficacy, reduce toxicity and predict non-responders in hope that 
alternative therapy can be chosen or individual dose adjustments can be made. Despite the extensive 
studies and some promising results, it remains unclear when and how pharmacogenetic testing should 
be routinely integrated into GIST management. 
Very few genotype-driven dose-optimization studies prospectively assessed objective response rate, 
progression-free survival, overall survival or other measures of efficacy as their primary endpoints, and 
have been translated into clinical practice. In regard to GIST, it is still an uphill road towards 
personalized medicine. The evidence is still too sparse to provide a solid relationship between germline 
variants and imatinib response, largely due to a lack of validated predictive polymorphisms. Furthermore, 
the way to the identification of translatable pharmacogenetic markers may be complicated by the 
inability to always take into account the effects of somatic genome, tumor heterogeneity, epigenetic 
factors, or additional unidentified prognostic factors. 
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